Geruining®
Description:

Geruining (Velaglucerase Beta for Injection) is a lysosomal enzyme. It exerts its therapeutic effect following cellular uptake via mannose receptor-mediated intracellular endocytosis. Geruining's molecular design utilizes CRISPR-Cas9 technology to achieve targeted knockout of the GnT1 gene. This gene is pivotal in protein glycosylation, catalyzing the conversion of high-mannose type glycans to complex-type or hybrid-type glycans. Knockout of this gene blocks further protein glycosylation, resulting in exposure of mannose residues. Consequently, Geruining achieves autonomous mannose exposure without requiring any additives or exogenous enzymes. Geruining is classified as a Class 1 innovative therapeutic

Indication: Geruining is indicated for long-term enzyme replacement therapy (ERT) in adult and adolescent patients (12 years and older) with Type 1 and Type 3 Gaucher disease
Ownership: Canbridge Pharmaceuticals Inc. holds the global development and commercialization rights for Geruining
Status: Geruining received marketing approval from the National Medical Products Administration (NMPA) on May 13, 2025, via the priority review pathway
Livmarli®
Description: Livmarli is an oral, minimally absorbed, reversible inhibitor of the ileal bile acid transporter (IBAT)
Indication: Cholestatic pruritus in patients with Alagille syndrome
Ownership: Exclusive rights to develop, commercialize, and under certain conditions, manufacture Livmarli in Greater China
Status: Livmarli was approved in the US in 2021, in the EU in 2022, and in Greater China in 2023
Hunterase®
Description:

Hunterase®, (iduronidase-2-sulfatase) is a recombinant human Enzyme Replacement Therapy (ERT)

Indication: Mucopolysaccharidosis type II (MPS II) or Hunter syndrome
Ownership: Exclusive license to develop and commercialize in Greater China from South Korea’s GC Pharma
Status: Hunterase is designated an orphan drug in the United States and Korea and is marketed in 12 countries. Hunterase was approved for marketing in China in September 2020
Learn more about Hunterase®